S. 1803Senate115th Congress (2017-2019)In Committee

MEDS Act

Introduced September 13, 2017

AI-Generated Summary

Updated April 15, 2026 at 5:59 PM UTC

The MEDS Act aims to make it easier for scientists and doctors to conduct medical research on marijuana. It updates the Controlled Substances Act to allow qualified researchers, manufacturers, and distributors to register with the Attorney General, sets faster NIH protocol reviews, establishes security and oversight rules, and removes certain international restrictions. The bill also requires guidance on good manufacturing practices and allows quota adjustments to meet research demand.

Key Provisions

  • Changes the Controlled Substances Act so that the Attorney General can register qualified researchers to work with marijuana for medical studies, using criteria like state licensing, protocol approval by the FDA or NIH, and security safeguards.
  • Requires the NIH to set up a voluntary, fast‑track review of research protocols, giving a decision within 30 days of submission.
  • Mandates the Attorney General to act on a complete registration application within 60 days, either approving it or issuing an order to show cause.
  • Sets security standards for storing research marijuana and allows limited protocol changes without a new application, unless the changes increase diversion risk.
  • Clarifies that international drug‑control rules (the Single Convention) do not block federally approved marijuana research.
  • Adds “marijuana” to the definition of “marihuana” in the CSA.
  • Creates a new registration category for manufacturers and distributors of marijuana for research or for making FDA‑approved drugs, with no limit on the number of registrants and a 30‑day decision deadline.
  • Orders the National Institute on Drug Abuse to publish good‑manufacturing‑practice recommendations for growing research marijuana within 180 days.
  • Amends quota language to allow increases to meet medical, scientific, and industrial needs.
  • Bars HHS from reinstating a separate interdisciplinary review process for non‑NIH‑funded marijuana research.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)

September 13, 2017

View full timeline
SenateIntro Referral

Introduced in Senate

September 13, 2017

SenateIntro Referral

Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)

September 13, 2017

Floor Debate

23 members

What members said about S. 1803 on the floor

12 Republicans11 Democrats
Amy Klobuchar
Sen. Amy KlobucharD-MN · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I rise to discuss a very important amendment that has broad support. That is the…

Richard Blumenthal
Sen. Richard BlumenthalD-CT · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, we have seen the chaos and confusion created by the President's rescission of DACA that has…

Sheldon Whitehouse
Sen. Sheldon WhitehouseD-RI · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, as the Senate considers the annual authorization of our military and national defense programs,…

John Thune
Sen. John ThuneR-SD · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, last week I came down to the Senate floor to talk about the need for tax reform. One of the most…

John Cornyn
Sen. John CornynR-TX · Sep 13, 2017

The following Senator is necessarily absent: the Senator from Florida (Mr. Rubio). Further, if present and voting, the Senator from Florida (Mr. Rubio) would have voted ``yea.'' Madam President, the…

Show 8 more
John McCain
Sen. John McCainR-AZ · Sep 13, 2017

Mr. President, I call up substitute amendment No. 1003. I ask unanimous consent that the reading of the amendment be dispensed with. Mr. President, I understand Senator Paul is on his way to discuss…

Rand Paul
Sen. Rand PaulR-KY · Sep 13, 2017

Mr. President, for the first time in 15 years, we are debating the congressional role in the declaration of war. We have fought the longest war in U.S. history under an original authorization to go…

Roy Blunt
Sen. Roy BluntR-MO · Sep 13, 2017

Mr. President, I join my colleague Senator Thune in talking about the Defense Authorization Act, which is the bill that is before the Senate right now. The preamble to the Constitution says that one…

Orrin G. Hatch
Sen. Orrin G. HatchR-UT · Sep 13, 2017

Mr. President, today, I am introducing a proposal that could substantially improve America's healthcare. Despite what some of my colleagues believe, it does not take a sweeping overhaul of ObamaCare…

Orrin G. Hatch
Sen. Orrin G. HatchR-UT · Sep 13, 2017

Mr. President, today, I am introducing a proposal that could substantially improve America's healthcare. Despite what some of my colleagues believe, it does not take a sweeping overhaul of ObamaCare…

John Barrasso
Sen. John BarrassoR-WY · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I think it is clear to people all across America that the U.S. healthcare system needs reform.…

Jon Tester
Sen. Jon TesterD-MT · Sep 13, 2017

Mr. President, thank you for the opportunity to speak on the floor. The images and stories we have witnessed in the aftermath of Hurricanes Harvey and Irma are devastating. I want to thank every…

Benjamin L. Cardin
Sen. Benjamin L. CardinD-MD · Sep 13, 2017

Mr. President, earlier this week, we commemorated the 16th anniversary of the attack on our country on September 11. It was a day that I think none of us will ever forget. We were attacked, and we…

Show 11 more
Debbie Stabenow
Sen. Debbie StabenowD-MI · Sep 13, 2017

Mr. President, the National Defense Authorization Act before us is more than just an important defense policy bill; it shows what we value as a nation. In Michigan, we value our freedom. We cherish…

Jerry Moran
Sen. Jerry MoranR-KS · Sep 13, 2017

Mr. President, thank you. Prior to arriving in the U.S. Senate after the election of 2010, I was a Member of the House of Representatives, and I am one of the 30 percent of us in Congress today who…

Joe Donnelly
Sen. Joe DonnellyD-IN · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I rise to discuss my legislation, which seeks to prevent American workers from losing their jobs…

Johnny Isakson
Sen. Johnny IsaksonR-GA · Sep 13, 2017

Mr. President, I rise for two purposes--principally, to support this legislation and to thank Ranking Member Reed and Chairman McCain and the other Members of the Senate for the contributions they…

Tammy Baldwin
Sen. Tammy BaldwinD-WI · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I rise to speak about an amendment that I have submitted to restore ``Buy American'' standards…

Mike Rounds
Sen. Mike RoundsR-SD · Sep 13, 2017

Mr. President, as the Senate considers the National Defense Authorization Act, or the NDAA, I rise today to discuss a simple amendment in support of my constituents in South Dakota who are military…

Richard J. Durbin
Sen. Richard J. DurbinD-IL · Sep 13, 2017

Mr. President, I want to stand in support of the statement just made by my colleague from the Commonwealth of Maryland. He knows, as I know, that our responsibilities as U.S. Senators include…

Christopher Murphy
Sen. Christopher MurphyD-CT · Sep 13, 2017

Mr. President, first let me lend my support to efforts to bring amendments before the floor later today or later this week with respect to strengthening our Nation's ``Buy American'' laws. This has…

Roger F. Wicker
Sen. Roger F. WickerR-MS · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, at some point during the course of this debate on the National Defense Authorization Act, the…

Christopher A. Coons
Sen. Christopher A. CoonsD-DE · Sep 13, 2017

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I would like to speak briefly about the amendment just voted upon by this Chamber, an amendment…

Bob Corker
Sen. Bob CorkerR-TN · Sep 13, 2017

Madam President, I agree with so much of what the Senator from Arizona just said. We are getting ready to go through a procedural motion that I just want to briefly explain. Senator Paul has offered…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued September 13, 2017

II

115th CONGRESS

1st Session

S. 1803

IN THE SENATE OF THE UNITED STATES

September 13, 2017

Mr. Hatch (for himself, Mr. Schatz, Mr. Gardner, Mr. Coons, and Mr. Tillis) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To improve medical research on marijuana.

1.

Short title

This Act may be cited as the Marijuana Effective Drug Studies Act of 2017 or the MEDS Act.

2.

Marijuana research

(a)

In general

Section 303(f) of the Controlled Substances Act (21 U.S.C. 823(f)) is amended—

(1)

by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;

(2)

by striking (f) The Attorney General and inserting (f)(1) The Attorney General;

(3)

by striking Registration applications and inserting the following:

(2)

Registration applications

;

(4)

in paragraph (2), as so designated, by striking schedule I each place that term appears and inserting schedule I, except marijuana,;

(5)

by striking Article 7 and inserting the following:

(4)

Article 7

; and

(6)

by inserting before paragraph (4), as so designated, the following:

(3)
(A)

The Attorney General shall register a practitioner to conduct research with marijuana if—

(i)

the applicant is authorized to dispense, or conduct research with respect to, controlled substances in schedules II, III, IV, and V under the laws of the State in which the applicant practices;

(ii)

the applicant’s research protocol—

(I)

has been reviewed and allowed by—

(aa)

the Secretary under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)); or

(bb)

the National Institutes of Health or another Federal agency that funds scientific research; or

(II)

in the case of nonhuman research that is not federally funded, has been voluntarily submitted by the applicant to, and approved by, the National Institutes of Health; and

(iii)

the applicant has demonstrated that there are effective procedures in place to adequately safeguard against diversion of the marijuana from legitimate medical or scientific use, in accordance with subparagraph (E).

(B)

The Attorney General shall grant an application for registration under this paragraph unless the Attorney General determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, the following factors shall be considered:

(i)

The applicant's experience in dispensing, or conducting research with respect to, controlled substances.

(ii)

The applicant's conviction record under Federal or State laws relating to the manufacture, distribution, or dispensing of controlled substances.

(iii)

Compliance with applicable State, Federal, or local laws relating to controlled substances.

(iv)

Such other conduct by the applicant that may threaten the public health and safety.

(C)

Not later than 90 days after the date of enactment of this paragraph, for purposes of subparagraph (A)(ii)(II), the National Institutes of Health shall establish a process that—

(i)

allows a researcher to voluntarily submit the research protocol of the researcher for review and approval; and

(ii)

provides a researcher described in clause (i) with a decision not later than 30 days after the date on which the research protocol is submitted.

(D)
(i)

Not later than 60 days after the date on which the Attorney General receives a complete application for registration under this paragraph, the Attorney General shall—

(I)

approve the application; or

(II)

serve an order to show cause upon the applicant in accordance with section 304(c).

(ii)

For purposes of clause (i), an application shall be deemed complete when the applicant has submitted documentation showing that the requirements under subparagraph (A) are satisfied.

(E)
(i)

A researcher registered under this paragraph shall store marijuana to be used in research in a securely locked, substantially constructed cabinet.

(ii)

Any other security measures required by the Attorney General under this paragraph to safeguard against diversion shall be consistent with those required for practitioners conducting research on other controlled substances in schedules I and II that have a similar risk of diversion and abuse.

(F)
(i)

If the Attorney General grants an application for registration under this paragraph, the applicant may amend or supplement the research protocol without reapplying if the applicant does not—

(I)

change the type of drug, the source of the drug, or the conditions under which the drug is stored, tracked, or administered; or

(II)

otherwise increase the risk of diversion.

(ii)

If an applicant amends or supplements the research protocol under clause (i), the applicant shall, in order to renew the registration under this paragraph, provide notice to the Attorney General of the amended or supplemented research protocol in the applicant's renewal materials.

(iii)
(I)

If an applicant amends or supplements the research protocol in a manner that involves a change to the type of drug, the source of the drug, or conditions under which the drug is stored, tracked, or administered or otherwise increases the risk of diversion, the applicant shall provide notice to the Attorney General not later than 30 days before proceeding on such amended or supplemental research protocol.

(II)

If the Attorney General does not object during the 30-day period following a notification under subclause (I), the applicant may proceed with the amended or supplemental research protocol.

(iv)

The Attorney General may object to an amended or supplemental research protocol under clause (i) or (iii) if additional security measures are needed to safeguard against diversion or abuse.

(G)

Article 28 of the Single Convention on Narcotic Drugs shall not be construed to prohibit, or impose additional restrictions upon, research involving marijuana that is conducted in accordance with this paragraph and other applicable provisions of this title.

(H)

If marijuana or a compound of marijuana is listed on a schedule other than schedule I—

(i)

the provisions of this subsection that apply to research with a controlled substance in the applicable schedule shall apply to research with marijuana or that compound, as applicable; and

(ii)

subparagraphs (A) through (G) of this paragraph shall not apply to research with marijuana or that compound, as applicable.

.

(b)

Conforming amendment

Section 102(16) of the Controlled Substances Act (21 U.S.C. 802(16)) is amended by inserting or marijuana after The term marihuana.

3.

Manufacturing of marijuana for clinical use

Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:

(k)

Registration of persons To manufacture and distribute marijuana

(1)

Manufacture and distribution for use in research

The Attorney General shall register an applicant to manufacture or distribute marijuana on behalf of the Federal Government to the extent that the marijuana is intended to be used exclusively for legitimate research and scientific uses, in accordance with the applicable requirements under subsection (a) or (b) for registration of manufacturers or distributors of controlled substances in schedule I or II.

(2)

Manufacture and distribution for commercial production of FDA-approved drugs

The Attorney General shall register an applicant to manufacture or distribute marijuana on behalf of the Federal Government exclusively for the purpose of commercial production of a drug containing or derived from marijuana that is approved by the Secretary under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), in accordance with the applicable requirements under subsection (a) or (b) of this section for registration of manufacturers or distributors of controlled substances in schedule I or II.

(3)

No limit on number of manufacturers and distributors

The Attorney General shall not impose a limit on the number of applicants eligible to be registered under paragraph (1) or (2).

(4)

Timing

Not later than 30 days after the date on which the Attorney General receives an application for registration under paragraph (1) or (2), the Attorney General shall—

(A)

grant the application; or

(B)

serve an order to show cause upon the applicant in accordance with section 304(c).

(5)

Determination of supply

In considering the factors under subsection (a) or (b), as applicable, for the purposes of registering an applicant eligible under paragraph (1) or (2) of this subsection, the Attorney General shall consider the demand from researchers for an adequate and uninterrupted supply of specific strains of marijuana and for marijuana grown pursuant to specific manufacturing processes.

(6)

Relation to the Single Convention on Narcotic Drugs

(A)

Constructive possession and control

The registration of manufacturers and distributors of marijuana under paragraphs (1) and (2) shall constitute constructive possession and control by the Federal Government for the purposes of the obligations under the Single Convention on Narcotic Drugs.

(B)

Article 28

Article 28 of the Single Convention on Narcotic Drugs shall not be construed to prohibit, or impose additional restrictions upon, the manufacturing of marijuana that is conducted in accordance with paragraph (1) or (2), as applicable, and other applicable provisions of this title.

.

4.

Good manufacturing practices

Not later than 180 days after the date of enactment of this Act, the National Institute for Drug Abuse shall develop and publish recommendations for good manufacturing practices for growing and producing marijuana (as defined in section 102 of the Controlled Substance Act (21 U.S.C. 802), as amended by this Act) for research.

5.

Quotas

Section 306(e) of the Controlled Substances Act (21 U.S.C. 826(e)) is amended in the third sentence by striking exceeds the aggregate of the quotas of all registrants under this section and inserting should be increased to meet the changing medical, scientific, and industrial needs for the controlled substance.

6.

Termination of interdisciplinary review process for non-NIH-funded researchers

The Secretary of Health and Human Services may not—

(1)

reinstate the Public Health Service interdisciplinary review process described in the guidance entitled Guidance on Procedures for the Provision of Marijuana for Medical Research (issued on May 21, 1999); or

(2)

create an additional review of scientific protocols that is conducted only for research on marijuana (as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802), as amended by section 2(b)) other than the review of research protocols performed at the request of a researcher conducting nonhuman research that is not federally funded, in accordance with section 303(f)(3)(A)(ii)(II) of the Controlled Substances Act (21 U.S.C. 823(f)(3)(A)(ii)(II)), as amended by section 2(a).